Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Biopharmetrics Approach for Drug Product Quality Control with Clinical Relevance.

Journal of pharmaceutical sciences·2020
Same author

Dissolution Edge Charts for Immediate Release Products and Their Applications: a Simulation Study to Aid the Setting of Specifications.

The AAPS journal·2019
Same author

Influence of drug property and product design on in vitro-in vivo correlation of complex modified-release dosage forms.

Journal of pharmaceutical sciences·2013
Same author

In vivo bioequivalence and in vitro similarity factor (f2) for dissolution profile comparisons of extended release formulations: how and when do they match?

Pharmaceutical research·2011
Same author

Bioavailability considerations in evaluating drug-drug interactions using the population pharmacokinetic approach.

Journal of clinical pharmacology·2010
Same author

Two commonly used methods for exposure-adverse events analysis: comparisons and evaluations.

Journal of clinical pharmacology·2009
Same journal

Gabapentin Extended Release Tablets in Healthy Subjects Under Fed Conditions: A Randomized, Open-Label, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Comparative Bioavailability Study.

Drugs in R&D·2026
Same journal

Development and Optimization of a Biphasic-Release Acetazolamide Tablet-in-Tablet Formulation.

Drugs in R&D·2026
Same journal

A Combination of the Tryptophan Hydroxylase Inhibitor Telotristat with the mTOR Inhibitor Everolimus as an Effective Strategy Against Neuroendocrine Tumors.

Drugs in R&D·2026
Same journal

Ustekinumab in the Management of Perianal Fistulizing Crohn's Disease: Current Evidence and Practical Strategies.

Drugs in R&D·2026
Same journal

HIF-1α siRNA Enhances the Efficacy of Erlotinib in Non-small Cell Lung Cancer: A Novel Strategy to Reverse Hypoxia-Induced Drug Resistance.

Drugs in R&D·2026
Same journal

Arylpiperazine Derivative NAF19 Inhibits Prostate Cancer Activity and Its Molecular Mechanisms.

Drugs in R&D·2026
See all related articles

Related Experiment Video

Updated: Jun 12, 2026

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

Drug-drug interaction pattern recognition.

John Z Duan1

  • 1Office of New Drug Quality Assessment, Office of Pharmaceutical Science, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA. john.duan@fda.hhs.gov

Drugs in R&D
|June 1, 2010
PubMed
Summary
This summary is machine-generated.

This study introduces a DDI pattern recognition approach to interpret drug-drug interaction results by analyzing changes in drug exposure metrics like AUC and Cmax. It aids in understanding the pharmacokinetic mechanisms driving these interactions.

More Related Videos

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Related Experiment Videos

Last Updated: Jun 12, 2026

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Area of Science:

  • Pharmacokinetics
  • Drug Development
  • Pharmacology

Background:

  • Drug-drug interactions (DDIs) are critical in drug development, influencing drug safety and efficacy.
  • Changes in drug exposure (absorption, distribution, metabolism, elimination) are a major concern during concomitant medication use.
  • Standard DDI studies report exposure changes (AUC, Cmax, tmax), but variations among these metrics require further interpretation.

Purpose of the Study:

  • To investigate the variability in changes of AUC, Cmax, and tmax during DDIs.
  • To understand the pharmacokinetic basis for observed differences in exposure changes.
  • To develop a systematic approach for interpreting DDI study results.

Main Methods:

  • Simulated pharmacokinetic data based on a one-compartment model were generated for 24 cases.
  • Independent and simultaneous variations of key pharmacokinetic parameters (bioavailability, clearance, volume of distribution, absorption rate) were simulated.
  • Relationships between parameter fold changes and exposure changes were plotted to identify patterns.

Main Results:

  • AUC is primarily influenced by clearance and bioavailability.
  • Cmax is affected by all four simulated parameters (clearance, bioavailability, volume of distribution, absorption rate).
  • tmax is mainly determined by clearance and absorption rate, with bioavailability having minimal impact.

Conclusions:

  • A DDI pattern recognition approach is proposed for didactical and practical interpretation of DDI studies.
  • This method integrates exposure changes, parameter variations, and mechanistic insights for a comprehensive understanding.
  • The approach facilitates quicker and better comprehension of the dominant processes in drug-drug interactions.